Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance
PLYMOUTH MEETING, Pa.–(BUSINESS WIRE)–Oct. 23, 2025– Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced preliminary results for Q3 2025, highlighted by the following: WAKIX® (pitolisant) franchise delivered net revenue of approximately $239 million in Q3 2025, representing 29% year-over-year revenue growth These results were driven by the highest ever quarterly increase in average number of patients of approximately 500 […]